Efinopegdutide Phase 2 trial (NCT04944992)
A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 145
- actual
- Start
- 4 Aug 2021 (actual)
- Primary completion
- 19 Oct 2022 (actual)
- Sponsor
- Merck Sharp & Dohme LLC
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Efinopegdutide | Experimental | Drug: Efinopegdutide 20 mg/mL | Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24. |
| Semaglutide | Active comparator | Drug: Semaglutide 1.34 mg/mL | Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 Weeks | Baseline and up to ~24 Weeks |
| Percentage of Participants Who Experienced an Adverse Event (AE) | Up to ~29 weeks |
| Percentage of Participants Who Discontinued Study Intervention Due to an AE | Up to ~24 weeks |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Mean Absolute Reduction From Baseline in LFC Measured by MRI-PDFF (Evaluated by BICR) After 24 Weeks | Baseline and up to ~24 Weeks |
| Mean Percent Change From Baseline in Body Weight After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in Total Cholesterol After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C) After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in Triglycerides (TG) After 24 Weeks | Baseline and up to ~24 weeks |
| Mean Percent Change From Baseline in Apolipoprotein B (apoB) After 24 Weeks | Baseline and up to ~24 weeks |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04944992.
Liver fat results posted against semaglutide
The registry's first primary outcome is the relative reduction in liver fat content by MRI-PDFF after 24 weeks.[1]
The posted mean relative liver fat reduction was 72.7% for the efinopegdutide group and 42.3% for the semaglutide group.[1]
The posted difference in least-squares means was 30.4 percentage points, with a 90% interval of 22.1 to 38.7.[1]
The posted share of participants with any adverse event was 88.9% for efinopegdutide and 72.6% for semaglutide.[1]
Sources
- 1A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver DiseaseClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.